AB Science (AB.PA): Initiation Of A New Phase 3 Study With Masitinib In Prostate Cancer, Following Encouraging Survival Results Obtained In A Phase 2 Study
2/21/2014 8:51:42 AM
PARIS, Feb. 20, 2014 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with docetaxel in first line treatment of metastatic Castrate Resistant Prostate Cancer (mCRPC).
Help employers find you! Check out all the jobs and post your resume.
comments powered by